# Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax

> **NIH NIH U19** · OKLAHOMA MEDICAL RESEARCH FOUNDATION · 2020 · $476,466

## Abstract

Summary/Abstract
Innate immune dysregulation causes the severe effects of SARS-CoV-2 infections. The unique ways this novel,
emergent pathogen evades and co-opts the host immune response is not known. A better understanding of the
virus-host interactions regulating the innate immune response in SARS-CoV-2 infections will provide a basis for
therapeutic interventions and vaccine development. The Immunophenotyping Assessment in a COVID-19
Cohort (IMPACC) study coordinates a national, multi-institution consortium, collecting detailed clinical data and
biologic samples from hospitalized COVID-19 infected individuals, with the goal of identifying immune
signatures/molecular biomarkers associated with clinical disease course, to allow the prioritization of clinical
interventions and decision making. This supplement supports the University of Oklahoma Health Sciences
Centers’ participation in IMPACC to facilitate screening and enrollment of inpatients with COVID-19. It also
examines the hypothesis that that ARID3a protein expression in low-density neutrophils is associated with the
proinflammatory state that occurs during COVID-19 infection. The proposed supplement research is within the
scope of the parent grant U19AI062629, Molecular and Immunologic Analysis of the Pathobiology of Human
Anthrax. Here, we outline the process by which we will recruit, enroll and retain subjects for the IMPACC study
at our health sciences center, and obtain the clinical information and laboratory samples required. Our group
has previously collected the same samples and similar clinical information as part of a previous NIH therapeutic
trial, IRC005, and we were a top enroller (3rd of ~40 sites participating) in that study. The additional hypothesis-
driven experimental low-density neutrophil study will be performed in collaboration with a talented and
experienced investigator, and will exploit the corresponding clinical data that will be collected as part of the
IMPACC study. Thus, the proposed study will not only help the IMPACC study towards a successful conclusion,
but also generate new insights into the basic biology of coronavirus-host interactions and may reveal a novel
mechanism for the differences in the innate immune responses to SARS-CoV-2 between those that recover from
disease requiring hospitalization, and those that progress to poor outcomes or delayed recovery.

## Key facts

- **NIH application ID:** 10213407
- **Project number:** 3U19AI062629-17S1
- **Recipient organization:** OKLAHOMA MEDICAL RESEARCH FOUNDATION
- **Principal Investigator:** Kenneth Mark Coggeshall
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $476,466
- **Award type:** 3
- **Project period:** 2020-09-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10213407

## Citation

> US National Institutes of Health, RePORTER application 10213407, Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax (3U19AI062629-17S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10213407. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*